Drug profile · INN
memantine hydrochloride
MEMANTINE MERZ
memantine hydrochloride (MEMANTINE MERZ) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — memantine hydrochloride
- US status
- approved
- Class
- Nervous system (N06)
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.89
Quick answer
memantine hydrochloride (MEMANTINE MERZ) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamate [NMDA] receptor negative allosteric modulator
Primary target: Glutamate [NMDA] receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is memantine hydrochloride?
memantine hydrochloride (MEMANTINE MERZ) is a glutamate [nmda] receptor negative allosteric modulator. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for memantine hydrochloride?
MEMANTINE MERZ is a marketed brand name for memantine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of memantine hydrochloride?
memantine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.